selenocystine has been researched along with Cancer of Liver in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SC; Hsu, WL; Liang, HL; Luo, YH; Nien, CY; Wahyuni, EA; Wu, PY; Yang, SH; Yii, CY | 1 |
| Chen, T; Fan, C; Fu, X; Li, X; Wong, YS; Zheng, W | 1 |
2 other study(ies) available for selenocystine and Cancer of Liver
| Article | Year |
|---|---|
Selenocystine induces oxidative-mediated DNA damage via impairing homologous recombination repair of DNA double-strand breaks in human hepatoma cells.
Topics: Antioxidants; Carcinoma, Hepatocellular; Cystine; DNA; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Humans; Liver Neoplasms; Organoselenium Compounds; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Recombinational DNA Repair | 2022 |
Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling.
Topics: Animals; Antibiotics, Antineoplastic; Antiviral Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cystine; DNA Damage; Doxorubicin; Drug Therapy, Combination; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Organoselenium Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |